Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

TABLE 9.3 Some Relationships Between Expenditures and Health Benefitsa

Pathogen (Target Population)

Vaccine Envisaged

Annualized Present Value of Potential Health Benefits (IME Units)

Annualized Present Value of Expenditures on Vaccines Necessary to Achieve Potential Health Benefits (dollars)

Dengue virus

(Infants and children in endemic areas; travelers to endemic areas)

Attenuated live vector virus containing gene for broadly cross-reacting protective antigen

9,558

241,803,765

Escherichia coli

(enterotoxigenic)

(Infants < 6 months)

A combination of purified colonization factor antigens and possibly other antigens

126,454

722,284,852

Genetically engineered attenuated strains

145,260

69,171,586

Hemophilus influenzae type b

(Infants)

Conjugated polysaccharide

210,943

526,603,421

Hepatitis A virus

(Susceptibles of all ages; children)

Attenuated live virus

15,112

1,058,021,429

Polypeptide recombinant vaccine produced in yeast

14,392

4,028,950,683

Hepatitis B virus

(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations)

Polypeptide produced by recombinant DNA technology

213,192

8,859,258,746

Japanese encephalitis virus

(Children in epidemic and and endemic areas; foreign visitors to epidemic regions)

Inactivated virus produced in cell culture

3,232

613,959,820

Mycobacterium leprae

(Immuno-prophylactic: all children in endemic areas. Immuno-therapeutic: all recently infected individuals)

Armadillo-derived M. leprae

88,481

270,619,575

Neisseria meningitidis

(Infants, 3–6 months)

Conjugated capsular polysaccharides, groups A,C,Y, and W135

13,754

708,114,155

Parainfluenza viruses

(Infants)

Trivalent, subunit vaccine (which must contain fusion proteins)

43,692

1,697,123,972

Plasmodium spp.

(All infants at risk, military personnel, travelers)

Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation

475,205

967,271,590

Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)

426,640

856,843,460



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement